Investor Presentaiton

Investor presentation First three months of 2017 Slide 70 Semaglutide significantly reduced the risk of major cardiovascular events with 26% vs placebo in SUSTAIN 6 Semaglutide demonstrated 26% reduction in composite CV outcome compared with placebo Patients with an event (%) 15 10 5 semaglutide Hazard ratio = 0.74 (95% CI: 0.58;0.95) Events: 108 semaglutide; 146 placebo p<0.001 for non-inferiority p=0.02 for superiority* placebo • • • Key results and next step Non-inferiority of semaglutide compared to placebo was confirmed for time to first MACE in people with type 2 diabetes Semaglutide reduced the risk of MACE by 26% driven by reductions of non-fatal stroke by 39%* and non-fatal MI by 26% Semaglutide significantly reduced the risk of nephropathy while increasing the risk of retinopathy complications • Next step: Novo Nordisk has submitted an NDA for semaglutide to regulatory authorities and expect regulatory feedback in Q4 2017 0 8 16 24 32 40 48 56 64 72 80 88 96 104 Weeks Note: p-value is two-sided, pooled data reported for both semaglutide and placebo MACE: Major adverse cardiovascular event; 3-point MACE comprises cardiovascular death, non-fatal myocardial infarction and non-fatal stroke; CI: Confidence interval *No adjustment for multiple tests *P-value <0.001 NDA: New drug application novo nordisk

View entire presentation